ArticleFrontiers in cardiovascular medicine2026
The association of remnant cholesterol inflammatory index with the risk of major adverse cardiovascular events in patients with angina undergoing percutaneous coronary intervention: a retrospective study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The remnant cholesterol-inflammation index (RCII), which combines remnant cholesterol (RC) and high-sensitivity C-reactive protein (hs-CRP), reflects both metabolic and inflammatory risks. This study aims to evaluate the association between RCII and the risk of major adverse cardiovascular events (MACE) in patients with angina undergoing percutaneous coronary intervention (PCI). Methods: The association between baseline RCII and MACE risk was evaluated using multivariable Cox regression, restricted cubic spline (RCS) analysis, and time-dependent receiver operating characteristic (ROC) curves. Results: A total of 2,171 angina patients undergoing PCI were included (mean age 65.32 ± 6.85 years, 61.4% male), with a median follow-up of 36 months, during which 363 MACE events (16.7%) occurred. In the fully adjusted Cox model, each standard deviation increase in RCII was associated with a 5% higher MACE risk (HR = 1.05, 95%CI: 1.04-1.07); compared with the lowest tertile, the HRs for T2 and T3 were 2.87 (95%CI: 2.03-4.04) and 4.42 (95%CI: 3.09-6.32). Subgroup analysis revealed that RCII was significantly associated with MACE risk across different age groups (<65 years and ≥65 years), sex, smoking status, and the presence of coronary artery disease (CAD) history, diabetes, and hypertension, with no significant interactions observed between subgroups. RCS analysis revealed a non-linear positive association ( Conclusion: Baseline RCII may be a potential clinical biomarker for assessing the risk of new-onset MACE in patients with angina undergoing PCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.